Sort publications on year

  • Pharmaco-Economics

    Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.

    HOOGENDOORN M, CORRO RAMOS I, BALDWIN M, LUCIANI L, FABRON C, DETOURNAY B, PMH RUTTEN-VAN MÖLKEN M.

    Int J Chron Obstruct Pulmon Dis ; 2019;14:447-456

  • Pharmaco-Economics

    Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.

    LIZÉE T, BASCH E, TRÉMOLIÈRES P, VOOG E, DOMONT J, PEYRAGA G, URBAN T, BENNOUNA J, SEPTANS A-L, BALAVOINE M, DETOURNAY B, DENIS F.

    J Thorac Oncol ; 2019;14(6):1012-1020

  • Pharmaco-Economics

    [Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies?]

    MARGIER J, BAFFERT S, LE CORROLLER-SORIANO AG, French Costing Group.

    Rev Epidemiol Sante Publique ; 2018;66(S2):S93-S99

  • Pharmaco-Economics

    Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study

    ARFI A, BAFFERT S, SOILLY AL, HUCHON C, REYAL F, ASSELAIN B, NEFFATI S, ROUZIER R, HÉQUET D.

    BMJ Open ; 2018;8(5):e020276

  • Pharmaco-Economics

    Multiple Source of Information to Characterize the Clinical, Therapeutic Management and Economic Burden of Patients with Multiple Sclerosis in France.

    EPSTEIN J, DETOURNAY B , GUILLEMIN F, DEBOUVERIE M, COUSIN M, TEHARD B, GAROT T, BITOUN L, SOUDANT M , DEPOORTERE PH, PAU D

    Value in Health ; 2017;20(9):a719

  • Pharmaco-Economics

    Le coût des hospitalisations pour hypoglycémie en France chez les patients diabétiques de type 2

    DETOURNAY B, HALIMI S, LEVY P, BEC M, TORRETON E, DEJAGER S.

    Revue d'Épidémiologie et de Santé Publique ; 2017;65(S3):S137-S138

  • Pharmaco-Economics

    Effect of Multiple Sclerosis on Work Productivity

    DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D

    Value in Health ; 2017;20(9):a725

  • Pharmaco-Economics

    The Direct Cost of Patients With Multiple Sclerosis In France

    DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B

    Value in Health ; 2017;20(9):a721

  • Pharmaco-Economics

    What is the budget impact of a new treatment or new health technology arriving on the market?

    DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; participants of round table No. 3 of Giens XXXIII

    Therapie ; 2017;72(1):93-103

  • Pharmaco-Economics

    Quel impact budgétaire pour l’arrivée d’un nouveau traitement ou d’une nouvelle technologie de santé ?

    DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; les participants à la table ronde n(o) 3 de Giens XXXIII.

    Therapie ; 2017;72(1):81-91

  • Pharmaco-Economics

    Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France

    FERNANDEZ H, JOURDAIN O, VILLEFRANQUE V, LEHMANN M, LAFUMA A, TRANCART M.

    BMJ Open ; 2017;7(9):e015571

  • Pharmaco-Economics

    Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.

    CLAUDEPIERRE P, FAGNANI F, CUKIERMAN G, DE CHALUS T, JOUBERT JM, LAURENDEAU C, GOURMELEN J, BREBAN M

    Joint Bone Spine ; 2019;86(1);69-75

  • Pharmaco-Economics

    Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)

    BOUAME M, ALI LAHMAR M, BOUAFIA MT, HAMMOUDI N, CHENTIR MT, ATHMANE MA, KARA S, TRANCART M, YILDIZ L, CHEYNEL J, SOUALMI R.

    J Med Econ ; 2018; 21(12):1213-1220

  • Pharmaco-Economics

    Modelling lifetime cost consequences of toric compared with standard IOLs in cataract surgery of astigmatic patients in four European countries

    LAURENDEAU C, LAFUMA A, BERDEAUX G

    J Med Economics ; 12(3):230-237

  • Pharmaco-Economics

    Modelling the lifetime economic consequences of glaucoma in France

    PHILIPPE NORDMANN J, LAFUMA A, BERDEAUX G

    J Med Econ ; 12(1):9-16